Technical Analysis for ZEAL - Zealand Pharma A/S

Grade Last Price % Change Price Change
grade C 21.02 -3.62% -0.79
ZEAL closed down 3.62 percent on Wednesday, August 21, 2019, on 45 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical ZEAL trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -3.62%
NR7 Range Contraction -3.62%
Gapped Up Strength -3.62%
Oversold Stochastic Weakness -3.62%
Stochastic Reached Oversold Weakness 1.12%
Below Lower BB Weakness 1.12%
Down 3 Days in a Row Weakness 1.12%

Older signals for ZEAL ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. Its products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump-based diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes. The company has license agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; and Protagonist Therapeutics, Inc. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.
Medicine Diabetes Chemotherapy Obesity Endocrine System Peptide Hormones Peptides Endocrinology Glucagon Like Peptide 1 Anti Diabetic Drugs Boehringer Ingelheim Severe Hypoglycemia
Is ZEAL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.55
52 Week Low 11.51
Average Volume 11,352
200-Day Moving Average 17.4335
50-Day Moving Average 21.8404
20-Day Moving Average 21.9274
10-Day Moving Average 21.7299
Average True Range 0.5594
ADX 17.88
+DI 23.3442
-DI 40.115
Chandelier Exit (Long, 3 ATRs ) 21.8718
Chandelier Exit (Short, 3 ATRs ) 22.4652
Upper Bollinger Band 23.1054
Lower Bollinger Band 20.7494
Percent B (%b) 0.11
BandWidth 10.744548
MACD Line -0.175
MACD Signal Line -0.0445
MACD Histogram -0.1305
Fundamentals Value
Market Cap 646.34 Million
Num Shares 30.7 Million
EPS -0.63
Price-to-Earnings (P/E) Ratio -33.37
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.35
Resistance 3 (R3) 21.38 21.30 21.30
Resistance 2 (R2) 21.30 21.22 21.29 21.28
Resistance 1 (R1) 21.16 21.16 21.12 21.13 21.26
Pivot Point 21.08 21.08 21.06 21.07 21.08
Support 1 (S1) 20.94 21.00 20.90 20.91 20.78
Support 2 (S2) 20.86 20.94 20.85 20.76
Support 3 (S3) 20.72 20.86 20.75
Support 4 (S4) 20.69